title: [Prevention of thrombosis of coronary aneurysms in patients with a history of Kawasaki disease].
abstract: Patients with coronary artery aneurysms caused by Kawasaki disease are at increased risk of coronary thrombosis and ischemia. To prevent coronary thrombosis, long-term anti-thrombosis using anti-platelet drugs, such as aspirin, dipyridamole, ticlopidine, clopidogrel, and abciximab, with or without warfarin is recommended by official guidelines. In fact, aspirin or aspirin with warfarin are the most frequently administered regimen in these patients with coronary aneurysms. However, there has been paucity of data and no randomized controlled study to determine the efficacy of these drugs. This short article attempts to summarize the efficacy and safety of these drugs based on currently available literatures and our multi-institutional experience.
authors.affiliation: Department of Pediatrics and Child Health, Kurume University School of Medicine.
authors.forename: Kenji
authors.initials: K
authors.lastname: Suda
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kudo
authors.forename: Yoko
authors.initials: Y
authors.lastname: Sugawara
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ishii
authors.forename: Toyojiro
authors.initials: T
authors.lastname: Matsuishi
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D002675:Child, Preschool; D003323:Coronary Aneurysm / Q000188:drug therapy*; D003328:Coronary Thrombosis / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin